

Appl. No. : 10/820,144

Applicant : Esther H. Chang Filed : April 8, 2004

TC/A.U. : 1632

Examiner

Docket No. : 2444-116 Customer No. : 06449 Confirmation No. : 6653

INFORMATION DISCLOSURE STATEMENT

Director of the United States Patent and Trademark Office P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith Form PTO-1449 listing publications that the Office may wish to consider in examination of the subject application.

Pursuant to 1.98(d), copies of the references are not included because they were previously submitted to the Office in prior application Serial No. 09/856,270, filed May 18, 2001, and to which priority is or has been claimed under 35 USC § 120.

Respectfully submitted,

By Dansara G. Ernot

Barbara G. Ernst Attorney for Applicants Registration No. 30,377

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

Suite 800, 1425 K Street, N.W.

Washington, D.C. 20005 Telephone: (202)783-6040

•			. 461	ak iy								
INFORMATION DISCHESSURE STATEMENT BY APPLICANT F						Complete if Known						
						Application Number 10/820,144						
						ng Da	ate	April 8, 2004				
						st Nar	med Inventor	Esther H. Chang				
						oup A	rt Unit	1632				
						amine	er Name					
Sheet		1	of	2	Atto	orney	Docket Number	2444-116				
				U	J.S. F	PATE	NT DOCUMENTS					
Examiner Initials*	Cite No.1						t Name of Pate d Code² of Cited		nt	Date of Publication of Cited Document MM-DD-YYYY		
	AA	5,693,5	5,693,509				Cotten et al.	Cotten et al.			Dec. 12, 1997	
	АВ	5,962,3	5,962,311				Vickham et al.			Oct.5, 1999		
	AC	5,994,1	5,994,109				Woo et al.			Nov.30, 1999		
	AD	6,410,010				Zhang et al.				Jun 25, 2002		
· · · ·												
			-			Ì						
				FOF	REIG	N PA	TENT DOCUMEN	TS				
		i i	Foreign Patent Documer									
Examiner Initials*	Cite No.1	Office ³ Code				nd ⁵	Name of Patentee or Applicant of Cited Document			Date of Publication of Cited Document MM-DD-YYYY T ⁶		
	AE	wo	94/242	94/24299			Boehringer Ingelheim Int'l GmBH		н о	Oct. 27, 1994		
	AF WO 97/38723		723			Immusol Inc.	Immusol Inc.		Oct. 23, 1997			
	AG	WO 98/40508				Barbara Sosno	snowski et al.		Sep. 17, 1998			
Examiner Signature								Date Considered				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

Complete if Known NOV 2 2 2004 **Application Number** 10/820,144 INFORMATION DISCLOSURE & Filing Date April 8, 2004 STATEMENT BY APPLICAN First Named Inventor Esther H. Chang Group Art Unit 1632 **Examiner Name** 2 2 Sheet of Attorney Docket Number 2444-116 NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), No.1 T² Initials* publisher, city and/or country where published AH CARDUCCI et al., Renal, Bladder and Prostate Cancers: Gene Therapy; Diagnossi and Treatment of Genitourinary Malgnancies, 1996, Kluwer Academic Publishers, Boston. ΑI COOPER, Oncogenes, by Jones and Bartlett Publishers; ISBN 0-86720-136-3, 1990 DEONARAIN, "Ligand-targeted receptor-mediated vectors for gene delivery," Expert Opinion AJ on Therapeutics Patents, GB, Ashley Publications, 8(1):53-69, January 1998. AK DOUGLAS et al., "Targeted adenoviral vectors for cancer gene therapy (Review)," International Journal of Oncology, 11:341-348, 1997 AL ECK et al., Goodman & Gilma's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, pp. 77-101, 1996 FEIGELSON et al., "Genetic Susceptibility to Cancer from xogenous and Endogenous AM Exposures," Journal of Cellular Biochemistry, 255:15-22 (1996) AN GURA, T., Science, 278:1041-1042, 1997 AO HULME, Receptor-Ligand Interactions-A Practical Approach, Oxford University Press. Walton Street, Oxford OX2 6DP, ISBN 0-19-963090-9 AP MICHAEL et al., "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway," Gene Therapy 1:223-232, 1994. AQ MILLER et al., "Targeted vectors for gene therapy," FASEB Journal, U.S. Fed. of American Society for Experimental Biology, 9(2): 190-1999, February 1, 1995. Report and Recommendations of the Panel to Assess the NIH Investment Research on AR Gene Therapy, 12/7/95 AS STAVRIDIS et al., "Construction of Transferrin-Coated Liposomes for In Vivo Transport of Exogenous DNA to Bone Marrow Erythroblasts in Rabbits," given as a communication at the NATO Advanced Studies Institute Conf., Cape Sounioin Beach, Greece, June 20-July 1. 1983. AT STRYER, Biochemistry, 1995, pp. 7, 8, 33-40, 938-939 ΑU VERMA et al., Nature, 389:239-242, 1997 ΑV WAGNER et al., "Transferrin - polycation conjugates as carriers for DNA uptake into cells," Proc. Natl. Acad. Sci. USA 87:3410-3414, May 1990. AW XU, "Transferrin-Liposome-Mediated p53 Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiation In Vitro," Human Gene Therapy, 8:467-475, March 1, 1997. Examiner Date Signature Considered

61PE

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.